Status:
COMPLETED
Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients
Lead Sponsor:
Niguarda Hospital
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether a higher dose of low molecular weight heparin (enoxaparin 40 mg b.i.d.) is superior than the standard prophylaxis dose (enoxaparin 40 mg o.d.) in redu...
Detailed Description
Coronavirus disease-19 (COVID-19 ), which is caused by SARS-CoV-2 infection, are apparently at high risk of venous thromboembolism (VTE), as a consequence of activation of the hemostatic system which,...
Eligibility Criteria
Inclusion
- All-comers patients aged \>=18 years and admitted to hospital with laboratory-confirmed SARS-CoV-2 infection
Exclusion
- Patients admitted directly to an intensive care unit;
- Estimated creatinine clearance \<15 ml/min/1.73m2;
- Patients needing anticoagulant for prior indication;
- Participants involved in other clinical trials;
- Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
Key Trial Info
Start Date :
May 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 25 2021
Estimated Enrollment :
189 Patients enrolled
Trial Details
Trial ID
NCT04366960
Start Date
May 14 2020
End Date
May 25 2021
Last Update
June 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, Italy, 20162